SCHEMBL5125065

SCHEMBL5125065

CCNC(=O)NCc1ccco1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.71
TDP1 Q9NUW8 2/20 0.69
ALDH1A1 P00352 4/20 0.60
GAA P10253 2/20 0.60
RAB9A P51151 2/20 0.57
TSHR P16473 2/20 0.57
TP53 P04637 1/20 0.56
HPGD P15428 1/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
MEN1 O00255 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX15 P16050 1/20 0.56
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD17B10 Q99714 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24575916 0.91 EPHX2 (0.83) EPHX2TDP1ALDH1A1GAARAB9A
SCHEMBL2755805 0.84 EPHX2 (0.68) EPHX2TDP1ALDH1A1GAARAB9A
SCHEMBL14970807 0.84 EPHX2 (0.82) EPHX2TDP1ALDH1A1GAARAB9A
SCHEMBL31556343 0.81 EPHX2 (0.68) EPHX2TDP1ALDH1A1GAARAB9A
SCHEMBL6360360 0.81 ALDH1A1 (0.68) EPHX2TDP1ALDH1A1TSHRHPGD
SCHEMBL16622593 0.81 EPHX2 (0.68) EPHX2TDP1ALDH1A1GAARAB9A
SCHEMBL48668 0.80 ALDH1A1 (0.62) EPHX2TDP1ALDH1A1GAARAB9A
SCHEMBL14694017 0.80 ALDH1A1 (0.66) EPHX2TDP1ALDH1A1TSHRHPGD
SCHEMBL18415483 0.80 POLB (0.77) EPHX2TDP1ALDH1A1RAB9AHPGD
SCHEMBL11596739 0.79 KMT2A (0.68) ALDH1A1GAAHPGDHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064876-A1 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione CELGENE CORPORATION 2008-03-13 US claimed
WO-2007136640-A2 PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE CELGENE CORPORATION (US) 2007-11-29 WO claimed
US-20080064876-A1 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione CELGENE CORPORATION 2008-03-13 US disclosed
WO-2007136640-A2 PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE CELGENE CORPORATION (US) 2007-11-29 WO disclosed
US-7186725-B2 Anti-inflammatory compositions and methods GENZYME CORPORATION (US) 2007-03-06 US disclosed
US-7186725-B2 Anti-inflammatory compositions and methods GENZYME CORPORATION (US) 2007-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064876-A1 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione TNF, DHPS, IDO1 EPHX2 1677/4885TDP1 1532/4885ALDH1A1 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.